Top Line: In the era of precision ablative radiotherapy, pancreatic cancer continues to nudge radiation oncologists to the edge of their comfort zones.
The study: Here is a retrospective look at a prospectively maintained cohort of 507 patients receiving stereotactic body radiotherapy (SBRT) for pancreatic cancer at the University of Pittsburgh. SBRT included a broad range of strategies including 18-25 Gy x 1 (BED with α:β of 3 = 126–233 Gy, 15%), 9-12 Gy x 3 (BED =108–180 Gy, 55%), and 5-8 Gy x 5 (BED = 67–147 Gy, 29%). Approximately one-third of cases were performed prior to or following surgery. A couple of trends were noted when looking at outcomes over the ensuing months. First, roughly a quarter were hospitalized within 90 days, primarily for infection (think: acute cholangitis). Over the same time period, 38 (7.5%) died, primarily from progression. The rate of grade 3+ GI toxicity (think GI bleeds) was 13% at a median of 11 months, and appeared to occur more often with higher BED treatments. One-third of grade 3+ events occurred more than 18 months out from treatment, which the authors highlight pretty well mirrors what is seen with rectal bleeding following prostate SBRT.
TBL: Gentler fractionation for ablative pancreatic radiation may well prove to ameliorate dose-limiting adjacent GI toxicity, but it will likely take a minimum of two years follow-up to tease it out. | Ellsworth, J Natl Compr Canc Netw 2025
The study: Here is a retrospective look at a prospectively maintained cohort of 507 patients receiving stereotactic body radiotherapy (SBRT) for pancreatic cancer at the University of Pittsburgh. SBRT included a broad range of strategies including 18-25 Gy x 1 (BED with α:β of 3 = 126–233 Gy, 15%), 9-12 Gy x 3 (BED =108–180 Gy, 55%), and 5-8 Gy x 5 (BED = 67–147 Gy, 29%). Approximately one-third of cases were performed prior to or following surgery. A couple of trends were noted when looking at outcomes over the ensuing months. First, roughly a quarter were hospitalized within 90 days, primarily for infection (think: acute cholangitis). Over the same time period, 38 (7.5%) died, primarily from progression. The rate of grade 3+ GI toxicity (think GI bleeds) was 13% at a median of 11 months, and appeared to occur more often with higher BED treatments. One-third of grade 3+ events occurred more than 18 months out from treatment, which the authors highlight pretty well mirrors what is seen with rectal bleeding following prostate SBRT.
TBL: Gentler fractionation for ablative pancreatic radiation may well prove to ameliorate dose-limiting adjacent GI toxicity, but it will likely take a minimum of two years follow-up to tease it out. | Ellsworth, J Natl Compr Canc Netw 2025

